# Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $486,851

## Abstract

Tuberous Sclerosis Complex (TSC) is a monogenic disorder with increased incidence of seizures, intellectual
disability (ID), and autism spectrum disorder (ASD). Although significant progress has been achieved in understanding
TSC, the ability to fully comprehend TSC as a neurodevelopmental disorder, and the shared molecular mechanisms
that may explain the overlapping phenotypes between TSC and ASD is hampered by the lack of suitable human
neuronal cell lines as well as challenges in establishing disease-relevant human isogenic cellular models. The
capability to reprogram somatic cells into induced pluripotent stem cells (iPSCs), and the recent advances in genome
editing technologies provide a timely opportunity to establish genetically matched sets of human iPSC lines that differ
exclusively at the disease-causing genetic alteration. Employing CRISPR/Cas9 genome editing, we have recently
generated such isogenic iPSC lines from two unrelated TSC patients, with a defined heterozygous inactivating
mutation in TSC1 or TSC2, respectively. Further, we have obtained iPSC lines from three additional unrelated TSC2
individuals, which will serve as a validation cohort ensuring robustness and reproducibility of our data. These iPSC
lines have allowed us to derive lineages of neural progenitor cells (NPCs), the cell of origin for the CNS
manifestations of TSC, and neural crest cells (NCCs), responsible for the non-CNS aspects of TSC. Initial
studies carried out with the genetically matched sets of TSC1-NPCs (Het, Null and Corrected-WT) confirm an
increase in cell size and activation of mTORC1 in TSC1 Het and Null cells. We observe distinct activation of
ERK1/2 signaling and an increase in MNK-eIF4E after treating NPCs with rapamycin. Interestingly, TSC1 Het
and Null NPCs when compared with the matched WT control reveal an increase in NPC proliferation as well as
neurite number and length, which are early-stage neurodevelopmental phenotypes linked to ASD. As
mTORC1, MEK-ERK a as well s MNK-eIF4E signaling regulate translation, we propose to generate
comprehensive transcriptome and translatome profiles in TSC1/2 Het, Null and Corrected-WT NPCs and
NCCs, which will define the underlying molecular changes upon TSC1/2 loss. Finally, we will undertake an
unbiased high-throughput single and combination drug screen in TSC1/2 isogenic sets of NPCs, in
collaboration with NIH-NCATS, to identify potential drugs that exert preferential impact on TSC1/2 Het and Null
cells. The top single and combination drugs will be independently validated in the Ramesh lab in multiple TSC
patient-derived NPC lines. The effects of compounds that show selective bias toward TSC1/2 Het or Null cells will be
further tested in secondary assays that will assess their ability to normalize transcriptome and translatome
signatures. The use of patient-specific, iPSC-derived NPCs and NCCs as genetically accurate human cellular
models for understanding the disease and for drug screening will provide...

## Key facts

- **NIH application ID:** 10168668
- **Project number:** 5R01NS109540-03
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** STEPHEN J HAGGARTY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $486,851
- **Award type:** 5
- **Project period:** 2019-06-15 → 2024-05-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10168668

## Citation

> US National Institutes of Health, RePORTER application 10168668, Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets (5R01NS109540-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10168668. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*